Microgynon (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol is a synthetic estrogen that stabilizes the endometrial lining and works with levonorgestrel to suppress the mid‑cycle luteinizing hormone surge. This inhibition prevents ovulation, while also contributing to thickened cervical mucus and an altered uterine environment that together reduce the chance of fertilization and implantation.

The dosing regimen for Microgynon is determined by the prescribing healthcare professional. Typically, the product is taken as a daily oral tablet according to a 21‑day active‑tablet schedule followed by a 7‑day pill‑free interval, but the exact plan should be confirmed with the prescriber.

Microgynon is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it may harm the fetus. It is also not recommended for breastfeeding women, as hormonal exposure can affect milk production and infant development. Alternative contraception should be discussed with a healthcare provider.

To order Microgynon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Microgynon contains a low‑dose estrogen (0.03 mg) combined with levonorgestrel, a widely used progestogen. Compared with higher‑dose formulations, it may have a slightly lower risk of estrogen‑related side effects while maintaining effective ovulation suppression. Its safety and efficacy profile is comparable to other second‑generation combined pills.

Microgynon tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack, protect from moisture and direct sunlight, and keep out of reach of children. Do not store in bathrooms or other humid environments.

Microgynon is taken orally, once daily, at the same time each day. Tablets can be swallowed with or without food. After a 21‑day course of active tablets, a 7‑day pill‑free interval follows, during which withdrawal bleeding typically occurs.

The most serious risks include venous thromboembolism (deep‑vein thrombosis and pulmonary embolism), arterial events such as stroke or myocardial infarction, severe liver dysfunction, and rare allergic reactions like anaphylaxis. Women with a history of clotting disorders, smoking over age 35, or certain cardiovascular conditions should avoid use.

Microgynon is contraindicated in women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disorders, uncontrolled hypertension, severe liver disease, or are smokers over 35 years of age. It should also be avoided in individuals with known hypersensitivity to any component of the tablet.